Factors affecting overall survival from the end of CTD chemotherapy
| Factor . | Univariate significance (OR; 95% CI) . | Multivariate significance (OR; 95% CI) . |
|---|---|---|
| Overall survival from the end of treatment | ||
| Number of organs | 0.69 (1.1; 0.5-2.1) | — |
| Performance status | < 0.0001 (5.2; 2.2-12.4)* | 0.01 (9.6; 1.9-16.2)* |
| Cardiac involvement | 0.30 (0.5; 0.1-1.8) | — |
| Liver involvement | 0.008 (4.1; 1.4-11.6) | NS |
| Renal involvement | 0.42 (1.5; 0.5-4.5) | — |
| Amyloid load on SAP scan | 0.082 (0.79; 0.61-1) | — |
| Any previous treatment | 0.30 (1.7; 0.58-5.4) | — |
| At least 2 mo on treatment | 0.002 (6.22; 1.9-19.4)* | NS |
| CTD or CTDa | 0.071 (1.4; 0.97-2.1) | — |
| Organ response | 0.14 (1.8; 0.81-4.22) | — |
| Any toxicity | 0.33 (1.7; 0.5-5.1) | — |
| Hematologic response | 0.002 (12.6; 2.6-60.3)* | 0.048 (6.3; 1.1-39.2)* |
| Event-free survival | ||
| Any previous treatment | 0.99 (0.99; 0.42-2.3) | — |
| No. of prior treatments | 0.87 (0.95; 0.56-1.5) | — |
| CTD or CTDa | 0.15 (1.2; 0.92-1.6) | — |
| Thalidomide maintenance | 0.033 (3.2; 1-9.7)* | 0.032 (3.6; 1.1-11.5)* |
| Toxicity | 0.98 (1; 0.44-2.2) | — |
| Factor . | Univariate significance (OR; 95% CI) . | Multivariate significance (OR; 95% CI) . |
|---|---|---|
| Overall survival from the end of treatment | ||
| Number of organs | 0.69 (1.1; 0.5-2.1) | — |
| Performance status | < 0.0001 (5.2; 2.2-12.4)* | 0.01 (9.6; 1.9-16.2)* |
| Cardiac involvement | 0.30 (0.5; 0.1-1.8) | — |
| Liver involvement | 0.008 (4.1; 1.4-11.6) | NS |
| Renal involvement | 0.42 (1.5; 0.5-4.5) | — |
| Amyloid load on SAP scan | 0.082 (0.79; 0.61-1) | — |
| Any previous treatment | 0.30 (1.7; 0.58-5.4) | — |
| At least 2 mo on treatment | 0.002 (6.22; 1.9-19.4)* | NS |
| CTD or CTDa | 0.071 (1.4; 0.97-2.1) | — |
| Organ response | 0.14 (1.8; 0.81-4.22) | — |
| Any toxicity | 0.33 (1.7; 0.5-5.1) | — |
| Hematologic response | 0.002 (12.6; 2.6-60.3)* | 0.048 (6.3; 1.1-39.2)* |
| Event-free survival | ||
| Any previous treatment | 0.99 (0.99; 0.42-2.3) | — |
| No. of prior treatments | 0.87 (0.95; 0.56-1.5) | — |
| CTD or CTDa | 0.15 (1.2; 0.92-1.6) | — |
| Thalidomide maintenance | 0.033 (3.2; 1-9.7)* | 0.032 (3.6; 1.1-11.5)* |
| Toxicity | 0.98 (1; 0.44-2.2) | — |
NS indicates not significant; —, not tested.
Statistically significant.